Published in Medical Letter on the CDC and FDA, April 26th, 2006
Approximately 30 positions in research and development were eliminated in the restructuring.
Chief Scientific Officer Dr. Gordon Letts emphasized that NitroMed's priority project is on schedule as development continues on an extended release formulation of BiDil. BiDil is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.